In the 118 countries, there are four priority areas for domestic and international investment to drive down deaths, alleviate suffering, cut transmission and contain spread of drug resistance.
3092
核心领域是扩大诊断和有效治疗对药物敏感的结核病（以预防耐多药结核病）。
For the core areas of expanded diagnosis and effective treatment for drug-susceptible TB (which will prevent MDR-TB), a total of US$ 2.6 billion is needed each year for the 2014-2016 period.
3093
从2014到2016年，这个领域每年需要26亿美元。
For 2011, funding of about US$ 2 billion was available.
3094
2011年获得的资金为20亿美元。
In low-income countries, especially in Africa, this is the largest area for increased financing.
3095
快速、有效治疗耐多药结核病领域每年需要13亿美元。
Prompt and effective treatment for multidrug-resistant TB requires an estimated total of US$ 1.3 billion per year.
3096
这是未来几年需要增加资金最多的领域。
This is where the greatest increase in funding is needed in the coming years.
3097
2011年获得的资金是5亿美元。
For 2011, funding of US$ 0.5 billion was available.
Uptake of new rapid diagnostics and associated laboratory strengthening, especially for the diagnosis of MDR-TB and for TB diagnosis among people living with HIV, requires US$ 600 million per year.
3099
感染艾滋病毒的结核病患者的抗逆转录病毒治疗由艾滋病毒规划及其捐助方供资。
Excluding antiretroviral treatment for TB patientsliving with HIV, which is financed by HIV programmes and their donors, about US$ 330 million is required for HIV-associated TB interventions, such as testing TB patients for HIV, ensuring regular screening for active TB disease among people living with HIV, and providing TB preventive treatment.
In addition to the US$ 1.6 billion annual gap in international financing for the critical implementation interventions above, WHO and partners estimate that there is a US$ 1.3 billion annual gap for TB research and development during the period 2014-2016, including clinical trials for new TB drugs, diagnostics and vaccines.